Literature DB >> 12828960

Liver disease in alcohol and hepatitis C.

M Mazen Jamal1, Timothy R Morgan.   

Abstract

The prevalence of hepatitis C is 7-10-fold higher in alcoholics than it is in the general population. Among alcoholics, the prevalence of hepatitis C is higher in alcoholics with advanced liver disease. Serum ALT and hepatitis C viral load may improve if alcoholic patients with hepatitis C stop drinking for more than 4 months.Up to 60% of patients with hepatitis C have a past history of alcohol use. In patients with hepatitis C, chronic alcohol consumption of more than 5 drinks per day increases the rate of liver fibrosis. Hepatitis C patients who ingest more than 5 alcoholic drinks per day are at increased risk for cirrhosis, hepatocellular carcinoma and, possibly, death from liver disease. Recent alcohol use decreases the response rate to interferon treatment. The detrimental effects of small amounts (3 or fewer drinks per day) of alcohol consumption in patients with hepatitis C are not known.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12828960     DOI: 10.1016/s1521-6918(03)00018-0

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  15 in total

1.  Molecular mechanisms involved in the interaction effects of alcohol and hepatitis C virus in liver cirrhosis.

Authors:  Valeria R Mas; Ryan Fassnacht; Kellie J Archer; Daniel Maluf
Journal:  Mol Med       Date:  2010-03-26       Impact factor: 6.354

2.  Alcohol-related and viral hepatitis C-related cirrhosis mortality among Hispanic subgroups in the United States, 2000-2004.

Authors:  Young-Hee Yoon; Hsiao-ye Yi; Patricia C Thomson
Journal:  Alcohol Clin Exp Res       Date:  2010-12-01       Impact factor: 3.455

3.  Ethanol administration impairs pancreatic repair after injury.

Authors:  Katrina J Mahan Schneider; Marc Scheer; Mallory Suhr; Dahn L Clemens
Journal:  Pancreas       Date:  2012-11       Impact factor: 3.327

Review 4.  Pathogenesis of alcoholic liver disease: the role of nuclear receptors.

Authors:  Maxwell Afari Gyamfi; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2010-05

Review 5.  Psychiatric and substance use disorders in individuals with hepatitis C: epidemiology and management.

Authors:  Jennifer M Loftis; Annette M Matthews; Peter Hauser
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  High prevalence of alcohol use among hepatitis C virus antibody positive injection drug users in three US cities.

Authors:  Jennifer V Campbell; Holly Hagan; Mary H Latka; Richard S Garfein; Elizabeth T Golub; Micaela H Coady; David L Thomas; Steffanie A Strathdee
Journal:  Drug Alcohol Depend       Date:  2005-08-29       Impact factor: 4.492

7.  Effects of a hepatitis C virus educational intervention or a motivational intervention on alcohol use, injection drug use, and sexual risk behaviors among injection drug users.

Authors:  William A Zule; Elizabeth C Costenbader; Curtis M Coomes; Wendee M Wechsberg
Journal:  Am J Public Health       Date:  2009-02-12       Impact factor: 9.308

Review 8.  Aberrant post-translational protein modifications in the pathogenesis of alcohol-induced liver injury.

Authors:  Natalia A Osna; Wayne G Carter; Murali Ganesan; Irina A Kirpich; Craig J McClain; Dennis R Petersen; Colin T Shearn; Maria L Tomasi; Kusum K Kharbanda
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

9.  Acetaldehyde accelerates HCV-induced impairment of innate immunity by suppressing methylation reactions in liver cells.

Authors:  Murali Ganesan; Jinjin Zhang; Tatiana Bronich; Larisa I Poluektova; Terrence M Donohue; Dean J Tuma; Kusum K Kharbanda; Natalia A Osna
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-08-06       Impact factor: 4.052

10.  Ethanol enhances hepatitis C virus replication through lipid metabolism and elevated NADH/NAD+.

Authors:  Scott Seronello; Chieri Ito; Takaji Wakita; Jinah Choi
Journal:  J Biol Chem       Date:  2009-11-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.